Medically reviewed on Sep 10, 2018
(ne si TOOM oo mab)
- Anti-EGFR Monoclonal Antibody IMC-11F8
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous [preservative free]:
Portrazza: 800 mg/50 mL (50 mL) [contains polysorbate 80]
Brand Names: U.S.
- Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor
- Antineoplastic Agent, Monoclonal Antibody
Necitumumab is a recombinant human IgG1 EGFR monoclonal antibody which binds (with a high affinity) to the ligand binding site of the EGFR receptor to prevent receptor activation and downstream signaling (Thatcher 2015).
Vdss: 7 L
Use: Labeled Indications
Non-small cell lung cancer (squamous), metastatic: First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin
Limitations of use: Not indicated for treatment of non-squamous non-small cell lung cancer.
There are no contraindications listed in the manufacturer's labeling.
Note: For patients with a prior grade 1 or 2 infusion reaction, premedicate (prior to all subsequent necitumumab infusions) with diphenhydramine (or equivalent). For patients with a recurrent grade 1 or 2 infusion reaction, premedicate (prior to all subsequent necitumumab infusions) with diphenhydramine (or equivalent), acetaminophen, and dexamethasone (or equivalent).
Non-small cell lung cancer (squamous), metastatic: IV: 800 mg on days 1 and 8 of each 3-week treatment cycle (in combination with gemcitabine and cisplatin); continue until disease progression or unacceptable toxicity (Thatcher 2015).
In the study, gemcitabine and cisplatin were administered for a maximum of 6 cycles, while patients without disease progression continued necitumumab as single agent therapy (Thatcher 2015).
Refer to adult dosing.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer’s labeling; however, based on pharmacokinetics, dosage adjustment is not likely necessary.
Dosing: Hepatic Impairment
Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; however, based on pharmacokinetics, dosage adjustment is not likely necessary.
Severe impairment: There is no dosage adjustment provided in the manufacturer’s labeling (has not been studied).
Dosing: Adjustment for Toxicity
Grade 3 rash or acneiform rash: Withhold treatment until symptoms resolve to grade 2 or lower, then resume necitumumab with the dose reduced to 400 mg for at least 1 treatment cycle. If symptoms do not worsen, may increase the dose to 600 mg and then 800 mg in subsequent cycles.
Grade 3 rash or acneiform rash that does not resolve to grade 2 or lower within 6 weeks: Permanently discontinue.
Grade 3 rash or acneiform rash that worsens or is intolerable at the 400 mg dose: Permanently discontinue.
Grade 3 skin induration/fibrosis: Permanently discontinue.
Grade 4 dermatologic toxicity: Permanently discontinue.
Electrolyte abnormality: Grade 3 or 4 electrolyte abnormality: Withhold treatment; may resume when electrolyte abnormality has improved to grade 2 or lower (replete electrolytes as appropriate).
Grade 1: Reduce infusion rate by 50%.
Grade 2: Interrupt infusion until signs/symptoms have resolved to grade 1 or 0, then resume with the rate reduced by 50% for all subsequent infusions.
Grade 3 or 4: Permanently discontinue.
Thromboembolic events: Serious or life-threatening VTE or ATE: Discontinue treatment.
Dilute for infusion in NS to a total volume of 250 mL (do not use solutions containing dextrose). Gently invert to mix; do not shake.
IV: Infuse over 60 minutes using an infusion pump. Infuse through a separate line. Flush with sodium chloride 0.9% at the end of infusion. Do not infuse with other medications or with electrolytes. Monitor for infusion reactions; reduce infusion rate by 50% for grade 1 infusion reaction; interrupt infusion for grade 2 infusion reaction.
Necitumumab should be administered prior to gemcitabine and cisplatin (Thatcher 2015).
Store intact vials at 2°C to 8°C (36°F to 46°F). Do not freeze. Store in original carton to protect from light. Do not shake. Solutions diluted for infusion in NS are stable for up to 4 hours at room temperature or 24 hours at 2°C to 8°C (36°F to 46°F); do not freeze or shake.
There are no known significant interactions.
Adverse reaction percentages reported as part of a combination regimen with gemcitabine and cisplatin.
Central nervous system: Headache (11%)
Dermatologic: Skin toxicity (79%; grades 3/4: 8%), skin rash (44%; grades 3/4: 4%), acneiform eruption (15%; grades 3/4: 1%)
Endocrine & metabolic: Hypomagnesemia (43% to 83%; grades 3/4: 20%), hypocalcemia (45%; grades 3/4: 6%; with albumin corrected: 36%; grades 3/4: 4%), hypophosphatemia (31%; grades 3/4: 8%), hypokalemia (28%; grades 3/4: 5%), weight loss (13%)
Gastrointestinal: Vomiting (29%), diarrhea (16%), stomatitis (11%)
1% to 10%:
Cardiovascular: Venous thromboembolism (9%; grades 3/4: 5%), arterial thromboembolism (5%; grades 3/4: 4%), pulmonary embolism (5%), cardiorespiratory arrest (3%), deep vein thrombosis (2%), cerebrovascular accident (≤2%), ischemia (≤2%), myocardial infarction (1%)
Dermatologic: Acne vulgaris (9%), paronychia (7%), pruritus (7%), xeroderma (7%), skin fissure (5%)
Immunologic: Antibody development (4%; neutralizing: 1%)
Ophthalmic: Conjunctivitis (7%)
Respiratory: Hemoptysis (10%)
Miscellaneous: Infusion related reaction (2%; grade 3: <1%)
Concerns related to adverse effects:
• Cardiopulmonary arrest: [US Boxed Warning]: Cardiopulmonary arrest and/or sudden death occurred in a small percentage of patients treated with necitumumab in combination with gemcitabine and cisplatin. Monitor serum electrolytes closely, including serum magnesium, potassium, and calcium, with aggressive replacement when warranted during and after necitumumab administration. Continue electrolyte monitoring for at least 8 weeks after the last dose. Some cardiopulmonary events were fatal; many of those patients had comorbid conditions (including a history of coronary artery disease, hypomagnesemia, COPD, and/or hypertension). Patients with significant coronary artery disease, MI within 6 months, uncontrolled hypertension or uncontrolled heart failure were excluded from the squamous cell non-small cell lung cancer study.
• Dermatologic toxicity: Dermatologic toxicity, including rash, dermatitis anceiform, acne, dry skin, pruritus, generalized rash, skin fissures, maculo-papular rash, and/or erythema occurs commonly; may be severe. Skin toxicity usually developed within the first 2 weeks of treatment and resolved within 17 weeks after onset. May require treatment interruption, dose reduction, or discontinuation. Patients should minimize exposure to the sun.
• Hypomagnesemia: [US Boxed Warning]: Hypomagnesemia occurred in a majority of patients receiving necitumumab in combination with gemcitabine and cisplatin; hypomagnesemia was severe in one-fifth of patients. Monitor for hypomagnesemia, hypocalcemia, and hypokalemia prior to each dose of necitumumab during treatment and for at least 8 weeks following completion of necitumumab. Withhold necitumumab for Grade 3 or 4 electrolyte abnormalities. Replete electrolytes as appropriate. May resume treatment when hypomagnesemia and related electrolyte abnormalities are improved to grade 2 or lower. The median time to development of hypomagnesemia was 6 weeks after treatment initiation.
• Infusion reactions: Infusion-related reactions have been reported with necitumumab, usually after the first or second infusion. Premedication was not routinely administered prior to the first dose in the squamous cell NSCLC study. Monitor for signs/symptoms of infusion reaction. Discontinue for serious or life-threatening reactions.
• Thromboembolism: Venous and arterial thromboembolic events (VTE and ATE) were observed with necitumumab, including grades 3 and 4 events and some fatalities. The most common VTEs were deep vein thrombosis and pulmonary embolism and the most common ATEs were cerebral stroke and ischemia and MI. Discontinue necitumumab for serious or life-threatening VTE or ATE. The incidence of VTE may be higher in patients ≥70 years of age (compared to patients under age 70).
• Non-squamous NSCLC: Necitumumab is not indicated for use in patients with non-squamous NSCLC. In a study of necitumumab in combination with pemetrexed and cisplatin for the treatment of metastatic non-squamous NSCLC, patients experienced increased serious and fatal toxicities and cardiopulmonary arrest/sudden death within 30 days of the last dose of necitumumab (compared to pemetrexed and cisplatin without necitumumab).
Serum electrolytes, including magnesium, potassium, and calcium (prior to each dose during treatment and for at least 8 weeks following completion). Signs/symptoms of infusion-related reactions, dermatologic toxicity, and thromboembolism.
Necitumumab is expected to cross the placenta. Based on animal data and the mechanism of action, necitumumab is expected to cause fetal harm if administered during pregnancy. Women of reproductive potential should use effective contraception during therapy and for 3 months after the last dose.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience vomiting, diarrhea, mouth sores, weight loss, headache, acne, itching, dry skin, or redness. Have patient report immediately to prescriber signs of blood clots (numbness or weakness on one side of the body; pain, redness, tenderness, warmth, or swelling in the arms or legs; change in color of an arm or leg; angina; shortness of breath; tachycardia; or coughing up blood), signs of low magnesium (mood changes; muscle pain or weakness; muscle cramps or spasms; seizures; tremors; lack of appetite; severe nausea or vomiting; or an abnormal heartbeat), signs of infusion reaction, signs of severe cerebrovascular disease (change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes), signs of electrolyte problems (mood changes, confusion, muscle pain or weakness, abnormal heartbeat, seizures, lack of appetite, or severe nausea or vomiting), severe dizziness, passing out, nail changes, chills, vision changes, eye pain, severe eye irritation, or severe skin irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about necitumumab
- Necitumumab Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 1 Review
- Drug class: EGFR inhibitors
Other brands: Portrazza